Increasing urbanization and infrastructure development in emerging economies present significant opportunities for the clay ...

Rising skin health awareness, income, and social media drive demand for easy, self-medicated anti-acne products, boosted by new tech and f ...

US drugmakers' shares drop 3% to 6% premarket European, Indian healthcare stocks drag down broader indexes Trump aims to shift pharma manufacturing to US, but analysts doubtful April 9 (Reuters ...

It comes as the heads of 30 pharma companies in the industry warned of an “exodus” of future investment in a letter to European Commission president Ursula von der Leyen. Picture: Anadolu ...

If you want to experience more of Sand & Sky's products, we suggest buying the Pink Clay Power Duo, which includes the aforementioned resurfacing face mask and the Australian Pink Clay Porefining ...

LONDON/BENGALURU April 3 (Reuters) - Drugmaker stocks gained a temporary reprieve on Thursday as U.S. President Donald Trump spared pharmaceutical products from reciprocal tariffs, but executives ...

However, it appears that the pharma industry has avoided a big blow – for now. A factsheet released by the White House said that finished pharmaceuticals are not subject to the reciprocal tariff.

At the Standalone during the January to March 2025 quarter, the Sudarshan Pharma Industries net profit at ₹9.95 crore also saw a sharp rise The net profit for the quarter reported buy the ...

Daily Mail journalists select and curate the products that feature on our site. If you make a purchase via links on this page we will earn commission - learn more Trying to achieve your best skin ...

The Trump administration’s threat of pharmaceutical tariffs could risk significant political backlash, as the drug industry and outside experts are raising red flags over worsening shortages and ...

Editor's note: An earlier version of this article mistakenly reported that pharmaceutical products are included in the tariffs. However, a fact sheet from the White House says that pharmaceuticals ...

Amid a broader selloff in the biopharma sector on Wednesday, Jazz Pharmaceuticals (NASDAQ:JAZZ) dropped ~6% after announcing a $145M settlement to resolve certain antitrust claims filed regarding ...